Accretion PharmaceuticalsNSE:ACCPL -1.81%18 Interest Coverage is 14.82 as of Mar. 2026, which is 136% above its 10-year median of 6.27. GuruFocus rates NSE:ACCPL with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 684 Drug Manufacturers companies, Accretion Pharmaceuticals ranks better than 54.97% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Accretion Pharmaceuticals's
Operating Income
for the
six
months ended in Mar. 2026 was ₹70.7 Mil. Accretion Pharmaceuticals's Interest Expense for the
six
months ended in Mar. 2026 was ₹-4.8 Mil.
Accretion Pharmaceuticals's interest coverage for the quarter that ended in Mar. 2026 was 14.82.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Accretion Pharmaceuticals's Interest Coverage or its related term are showing as below:
NSE:ACCPL'
s Interest Coverage Range Over the Past 10 Years
Min: 0.83 Med: 6.27 Max: 16.21
Current: 16.21
NSE:ACCPL's Interest Coverage is ranked better than 54.97% of 684
companies
in the Drug Manufacturers industry
Industry Median: 12.765
vs NSE:ACCPL: 16.21
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Accretion Pharmaceuticals Interest Coverage Related Terms
Accretion Pharmaceuticals Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:ACCPL vs LLY, JNJ, ABBV: Interest Coverage Comparison
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Pharmaceuticals (NSE:ACCPL) has a Interest Coverage of 14.82 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Accretion Pharmaceuticals and its competitors. This is 136% above median its historical median of 6.27. Over the past decade, Accretion Pharmaceuticals' Interest Coverage has ranged from 0.83 to 16.21. According to the industry distribution chart, Accretion Pharmaceuticals ranks #308 out of 684 companies in the Drug Manufacturers industry, placing it in the top 45%.
Is Accretion Pharmaceuticals' Interest Coverage too high?
Accretion Pharmaceuticals' current Interest Coverage of 14.82 is 136% above median its 10-year median of 6.27. Over the past 10 years, this metric has ranged from a low of 0.83 to a high of 16.21. The Drug Manufacturers industry median Interest Coverage is 12.77. Accretion Pharmaceuticals' value of 14.82 is 16.1% above this industry median. Based on the distribution chart, Accretion Pharmaceuticals ranks #308 out of 684 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Accretion Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' Interest Coverage compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #308 out of 684 companies for Interest Coverage. This puts Accretion Pharmaceuticals in the upper half of its industry. The industry median Interest Coverage is 12.77. Accretion Pharmaceuticals' value of 14.82 is 16.1% above this benchmark. Historically, Accretion Pharmaceuticals' own Interest Coverage has ranged from 0.83 to 16.21 over the past decade. While the company's 10-year median is 6.27 vs. the industry median of 12.77, Accretion Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current Interest Coverage of 14.82 is 16.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Accretion Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current Interest Coverage is 14.82, which is 136% above median its own 10-year median of 6.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current Interest Coverage of 14.82. The current Interest Coverage is 14.82, which is 136% above median its 10-year median of 6.27 and 16.1% above the Drug Manufacturers industry median of 12.77. Accretion Pharmaceuticals' overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current Interest Coverage is 14.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
18GF Score
Get the complete analysis for NSE:ACCPL
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 